Back to customer servicesPharma medical, R&D, and market access teams

The baseline is ready, but your teams are using different versions.

Medical, development and access teams repeatedly search for materials. When a new study appears, nobody can clearly explain whether existing claims are affected.

How does this scope address your concerns?

Will an annual fee only buy repeated article lists? Will 'updates' be created without meaningful new evidence?

When this scope fits

For teams with a reusable baseline that want to maintain the same product and indication over time.

When the scope needs adjusting

This does not replace pharmacovigilance, statutory safety monitoring or trial execution. If a baseline is missing, define its construction separately; maintenance fees do not include a complete new baseline.

REAL SOURCES · ILLUSTRATIVE REQUEST · DOWNLOADABLE SAMPLE

One product, three teams, one change log

Download sample packZIP

From scan to shared version

01
Baseline v1
Five questions, evidence cutoff and existing claims
02
Scan 01
Assume one candidate source; claim impact not yet determined
03
Professional review
Check population, results and corrections; flag unresolved items
04
Quarterly version v2
Affected claims, unchanged questions and next triggers

This illustrates a change log, not an actual product-label revision. Annual allowances follow the existing package.

Check	Finding / sample content	Use
Candidate source	“Newly published” and “changes the conclusion” are separate fields	Review and mark included, excluded or unresolved
No change detected	Retain databases, searches, date and scan results	Explain coverage in the quarterly report without inventing findings

SOURCES USED IN THIS EXAMPLE

FDA: Prescribing Information Resources

Prepared 5 Oct 2026 · Selected references, not an exhaustive systematic search

Scope & acceptance

Work covered by the quote

Illustrative scope: 1 product, 1 indication and 5 agreed questions; 12 scans, up to 120 new full texts annually, 4 professional update reports and 2 internal discussions.

Pilot reference: CNY 200,000–1,000,000+ per year. Fictional budget: CNY 240,000—scans and maintenance CNY 120,000; professional reports and discussions CNY 120,000. Quarterly payments: CNY 60,000 each. Baseline construction, new indications, full Meta-analyses, models or regulatory submissions are quoted separately.

Acceptance criteria

Each update records the baseline, changes, sources and review status. Scans with no new studies record no detected change rather than manufacture new findings.

Checking the evidence

Allowances follow illustrative scopes in the current pilot proposal. Customer situations, walkthroughs and budgets are fictional examples, not actual orders, product findings or validated savings.
A confirmed reusable product baseline, agreed-question list, and new or corrected sources; scan dates and review status are retained.

Workflow and inputs

From inputs to delivery

Explore the workflow and deliverable structure. This preview does not run searches, read real records or produce medical findings.

01 / WORKFLOW PREVIEW

Define the task

Illustrative request: a medical-affairs team wants to maintain 5 questions for one product for development and access colleagues.

Methods, sources and professional responsibilities

THE BASIS FOR THIS SCOPE

Why this approach? Inspect the basis.

Check the match between product, population, use conditions and outcomes before defining a supported claim.

OFFICIAL GUIDANCE

FTC · Health Products

Federal Trade Commission · US

Does the research match the product claim?

Scientific support for health-product claims should match the product and claim, rather than merely a similar ingredient.

Scope & access conditions

This is US guidance. Other markets require separate assessment; it is not an approval or compliance conclusion.

Open official source

PUBLIC DATABASE

ClinicalTrials.gov

NLM / NIH

Check studies and reported results

Review study objectives, eligibility, locations, status and reported results, then identify questions for the clinical team.

Scope & access conditions

Sponsors or investigators submit the records. A listing is not government approval of safety or effectiveness, or a determination that you should participate.

Read the official description

Open official source

METHOD REFERENCE

GRADE · Cochrane Handbook

Cochrane · Chapter 14

Show effect size and confidence separately

Present important outcomes, relative and absolute effects, available data and certainty, with reasons for downgrading.

Scope & access conditions

GRADE evaluates a body of evidence for a particular outcome. Database inclusion or one study does not automatically establish high certainty.

Open official source

These references support problem definition and evidence appraisal. Your conclusions still require project-specific sources and professional review.

The value of this commissionEOS retains versions and claim changes for fixed product questions, with applicability and action owners.

Annual drug evidence maintenanceCompare alternatives and value

Which new findings require changes to claims, comparisons or study plans?

What to assess	IQVIA	Evidence OS · Commissioned scope
Service focus	IQVIA supports synthesis and updates from development to submission.	EOS retains versions and claim changes for fixed product questions, with applicability and action owners.
When to choose	Established global services suit multi-market submissions, major ITCs and full lifecycle outsourcing.	Example: one product and indication, five questions, twelve scans, four reports and up to 120 full texts.

What the fee pays for: Planning reference: CNY 200,000–1,000,000+ annually; full reviews, model rebuilding and new markets are separate.
Value beyond this task: Build a transferable annual product baseline with consistent source identities across teams.
How to assess value: Measure repeat-search hours, source reuse and time to human confirmation of changes; no sales-growth guarantee.

Check review cadence, medical reviewers, pharmacovigilance boundaries and response windows.

CHECK THE OFFICIAL SERVICE SCOPEIQVIA · Evidence Synthesis fact sheet

Reuse and updates after delivery

Teams can discuss the same evidence version. Included scans and reports are not charged again per article; additional work is agreed first.

Agree reuse rights, retention and export periods, and future update fees when scoping.

Questions before commissioning

Can we maintain several indications?

This illustration covers 1 indication. Additional scope requires a review of material volume, agreed questions and review work.

What if there is no important change all year?

The scan scope and absence of detected changes are still recorded. Fees cover the agreed scans and professional maintenance; renewal is discussed against actual needs.

Are automated subscriptions and enterprise accounts already available?

The page currently presents proposals for discussion and request drafts. Accounts, automated delivery, team configuration and formal delivery must be arranged per project; they are not activated by viewing this page.

Define the delivery for your actual question.

Add your goal, available inputs and timing. Agree scope, review responsibilities and a quote before commissioning.

Request scope & quote

Explore other situations

Pharma medical, R&D, and market access teams

Your research budget is due. Which evidence is the product actually missing?

Receive a product evidence map, a claim-to-source table and a prioritised list of evidence gaps.

CNY 50,000–200,000 per packageSee the deliverable